Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
GamaMabs Pharma logo — Advancing the future of immuno-oncology with innovative mono...

GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments

Founded 2012 7 employees Series B Total: $18.10M Biotechnology, Health Care +1

General Information

Company Name GamaMabs Pharma
Founded Year 2012
Employees 7
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

Get notified when GamaMabs Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About GamaMabs Pharma

GamaMabs Pharma is a biotechnology company focused on advancing the future of immuno-oncology with innovative monoclonal antibody treatments. The company's main program, GM102, targets the anti-Müllerian hormone receptor (AMHR2) in gynecological cancers and is currently in the phase Ia/Ib stage. GamaMabs utilizes EMABling® glyco-engineering technology to enhance tumor cell destruction by activating immune cells. Founded in June 2013 in Toulouse, France, GamaMabs collaborates with prestigious academic and private partners and employs professionals with extensive experience in preclinical and clinical development. The company leverages technologies created by LFB BIOTECHNOLOGIES, a French biopharma company, and has received a €15.00M Series B investment from IXO Private Equity, Alto Invest, InnoBio, Andera Partners, and IRDInov. GamaMabs' primary objective is to advance its monoclonal antibodies to the stage of Clinical Proof of Concept. With its focus on immuno-oncology and strategic partnerships, GamaMabs is poised to make significant strides in the biotechnology and healthcare industries.

Taxonomy: immuno-oncology, monoclonal antibodies, cancer treatment, pharmaceuticals, clinical development, glyco-engineering, oncology research, collaborations, LFB BIOTECHNOLOGIES, EMABling® technology, HuMabFc technology, gynecological cancers, French biopharma, drug development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 5
Investor Investor Investor
•••• •••• 		15 Dec 2015
Series A •••••• 1
Investor
30 Sep 2013
Non Equity Assistance •••••• 1 •••• •••• 01 Jan 2012

GamaMabs Pharma Alternatives & Competitors

GamaMabs Pharma vs
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc. Canada

HARNESSING NATURE TO BEAT CANCER

5 employees
Biotechnology, Pharmaceutical
GamaMabs Pharma vs
LFB Biomanufacturing
LFB Biomanufacturing France

Your CDMO partner for antibodies and recombinant proteins

153 employees
Biotechnology, Manufacturing
GamaMabs Pharma vs
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. United States

Innovative pediatric immunotherapies for Real-life Possibilities

Post Ipo Equity
59 employees
Biotechnology, Health Care

FAQ About GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments
GamaMabs Pharma was founded in 2012.
GamaMabs Pharma operates in the following industries: Biotechnology, Health Care, Health and Wellness.
GamaMabs Pharma has approximately 7 employees.
GamaMabs Pharma has completed 3 funding rounds, raising a total of $18.10M. The latest funding stage is Series B.
Top alternatives and competitors to GamaMabs Pharma include Alpha Cancer Technologies Inc., LFB Biomanufacturing, Y-mAbs Therapeutics, Inc., Aegera Therapeutics Inc., Apexigen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GamaMabs Pharma and Alpha Cancer Technologies Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors GamaMabs Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy